Add like
Add dislike
Add to saved papers

Anatomic and biomechanical analysis of the arthroscopic wafer procedure.

The ulnar impaction syndrome is a common clinical entity that is most often associated with positive ulnar variance and is characterized by triangular fibrocartilage complex (TFCC), lunate, and/or distal ulnar pathology. Traditional treatment for symptomatic ulnar impaction syndrome has been conservative; however, in cases refractory to nonoperative management, formal ulnar shortening has been successful in long-term clinical series. Recently, arthroscopic ulnar shortening, the "arthroscopic wafer procedure" (AWP) (debridement of the perforated TFCC margins and limited ulnar head resection using a motorized burr) has become an option to treat this clinical syndrome. In an attempt to evaluate the biomechanical efficacy of the AWP, an experimental study was undertaken using nine ulnar positive cadaver forearms. Each specimen was evaluated biomechanically using axial load cells and pressure-sensitive film to evaluate the effect of serial resection of the TFCC and distal ulna on axial load and ulnar carpal pressures. The results of this experimental study revealed a statistically significant unloading of the ulnar aspect of the wrist after excision of the centrum of the TFCC and resection of the radial two-thirds width of the ulnar head, to a depth of subchondral bone resection. Furthermore, additional bony resection tended to correlate favorably with the stage of TFCC pathology noted, i.e., the more advanced the stage, the more resection necessary to unload the ulnar aspect of the wrist. Based on this biomechanical study, a limited clinical series has been initiated with early favorable results. The AWP biomechanically unloads the ulnar carpal complex, and therefore has a theoretical potential of relieving the symptoms of the ulnar impaction syndrome.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app